NCT04500912已完成不适用
Comparison of the Supraflex Cruz 60 Micron Stent Strut Versus the Ultimaster Tansei 80 Micron Stent Strut in High Bleeding Risk PCI Population
Pieter C.Smits11 个研究点 分布在 1 个国家目标入组 736 人开始时间: 2020年9月14日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 736
- 试验地点
- 11
- 主要终点
- Net Adverse Clinical Endpoints (NACE)
研究概览
简要总结
The study compares the outcome of the ultrathin stent strut Supraflex Cruz stent to the thin stent strut Ultimaster Tansei stent in a PCI population at high risk for bleeding (HBR).
详细描述
Study design: An Investigator-initiated, multi-center, randomized clinical trial in HBR patients receiving PCI with Supraflex Cruz or Ultimaster Tansei stents
Study population: 2 x 368 (736) patients, who undergo a PCI and are at high risk for bleeding (HBR).
Intervention: Patients are treated according to the randomized regimen at index PCI and at planned staged procedures. Either with the ultrathin stent strut Supraflex Cruz stent to the thin stent strut Ultimaster Tansei stent
DAPT treatment (combination and duration) is according to the Guidelines of the European Society of Cardiology for Myocardial Revascularization.
Follow-up is scheduled at 1 month, 6 months and 12 months post index PCI procedure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
盲法说明
Patient will be blinded for the stent that is used
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients are eligible for inclusion into the study if the following criteria are met.
- •Patients of 18 years and above
- •Written or witnessed oral consent to participate in the study
- •Native coronary artery lesions eligible for PCI with stents with no restrictions in number of lesions and stents, vessel size or lesion complexity, apart from stent thrombosis.
- •Patients at high risk for bleeding according to the HBR ARC criteria: Patients meet the HBR ARC criteria if ≥1 major or ≥2 minor criteria are met.
- •Major HBR criteria are the following:
- •Clinical indication for treatment with oral anticoagulants (OAC/NOAC) for at least 12 months
- •Severe or end-stage chronic kidney failure (GFR ≤ 30 ml/min)
- •Hemoglobin (Hb) level at screening < 11g/dl or < 6.8 mmol/l
- •Spontaneous bleeding requiring hospitalization or transfusion in the past 6 months or at any time, if recurrent
- •Moderate or severe baseline true thrombocytopenia (platelet count <100 *10^9/L)
- •History of chronic bleeding diathesis, like: leukemia, haemophilia, vitamin K deficiency, Factor V or VII deficiency etc.
- •Liver cirrhosis with portal hypertension
- •Active malignancy (other than skin) within the past 12 months
- •Spontaneous intracranial haemorrhage ICH (at any time)
- •Traumatic intracranial haemorrhage ICH within 12 months
- •Presence of a brain arterio-venous malformation (AVM)
- •Moderate or severe ischemic stroke within the past 6 months
- •Nondeferrable major surgery on DAPT after PCI
- •Recent major surgery or major trauma within 30 d before PCI
- •Minor HBR criteria are the following:
- •Age ≥ 75 years
- •Moderate chronic kidney disease (GFR >30 and <60 ml/min)
- •Hemoglobin (Hb) 11-12.9 g/dL / 6.8-8.0 mmol/l for men and 11-11.9 g/dL / 6.8-7.4 mmol/l for women
- •Any ischemic stroke at any time not meeting the major criterion
- •Spontaneous bleeding requiring hospitalization or transfusion within the past 12 months
- •Need for chronic treatment with steroids or non-steroidal anti-inflammatory drugs
排除标准
- •Patients are not eligible if any of the following applies:
- •Treated with stents other than Supraflex Cruz or Ultimaster within 6 months prior to index procedure
- •Treatment of lesions with stent thrombosis
- •Treatment of venous or arterial coronary grafts
- •Treated for stent thrombosis in 12 months prior to index PCI procedure
- •Treated with a bioresorbable scaffold 3 years before index PCI procedure
- •Cardiogenic shock at index procedure
- •Active SARS-CoV-2 infection or suspicion of SARS-CoV-2 infection
- •Cannot provide written informed consent
- •Under judicial protection, tutorship or curatorship
- •Unable to understand and follow study-related instructions or unable to comply with study protocol
- •Active bleeding requiring medical attention (BARC≥2) at index PCI
- •Life expectancy less than one year
- •Known hypersensitivity or allergy for aspirin, clopidogrel, ticagrelor, prasugrel, cobalt chromium or sirolimus
- •Any anticipated PCI after index PCI, unless planned and scheduled at index PCI
- •Participation in another stent or drug trial
结局指标
主要结局
Net Adverse Clinical Endpoints (NACE)
时间窗: 1 year
The primary endpoint Net Adverse Clinical Endpoints (NACE) defined as a composite of cardiovascular death, myocardial infarction, target vessel revascularization, stroke and bleeding events defined as BARC 3 or 5 at 12 months follow-up after the index PCI.
次要结局
- The composite of cardiovascular death, myocardial infarction, stroke and major bleed BARC 3 and 5(1 year)
- Bleeding events(1 year)
- Transfusion rates(1 year)
- Target vessel failure (TVF)(1 year)
- Stent thrombosis(1 year)
- Myocardial infarction(1 year)
- Event rates according to the PRECISE-DAPT(1 year)
- The composite of cardiovascular death, myocardial infarction and stroke(1 year)
- Urgent target vessel revascularization(1 year)
- Non-target vessel revascularization(1 year)
- Clinically indicated target vessel revascularization(1 year)
- Procedural success(At completion of the baseline PCI)
- Device success(At discharge of baseline hospitalisation, on average 3 days)
- Major adverse cardiac and cerebral events (MACCE)(1 year)
- Target Lesion Failure (TLF)(1 year)
- Major or clinically relevant non-major bleeding (MCB)(1 year)
研究者
Pieter C.Smits
MD, PhD
Research Maatschap Cardiologen Rotterdam Zuid
研究点 (11)
Loading locations...
相似试验
已完成
不适用
Comparison of the Supraflex Cruz 60 micron stent strut versus the Ultimaster Tansei 80 micron stent strut in High Bleeding Risk PCI populatioPCINL-OMON49235Research Maatschap Cardiologen Rotterdam Zuid736
已完成
不适用
Comparison of Covered and Bare Stent in TIPSCirrhosisNCT02540382Beijing Shijitan Hospital, Capital Medical University258
已完成
不适用
A Superiority Trial of the SUPERA Peripheral Stent System in Patients With Femoro-popliteal Artery DiseasePeripheral Arterial DiseaseNCT03941314Kantonsspital Winterthur KSW300
已完成
Unknown
Comparison of secondary stent types for stent occlusion after plastic stent placement for unresectable malignant hilar biliary obstructioThe cases of the stent obstruction after plastic stent placement for unresectable malignant hilar biliary obstructionJPRN-UMIN000051479Gifu municipal hospital350
终止
4 期
SERIES III RUN-IN Clinical Trial: A Comparison of the Supralimus® Stent With the Xience V™ StentCoronary Artery DiseaseNCT00917163Sahajanand Medical Technologies Limited13